Community curated by people like you

Biologic therapies stories

Aug 27, 2026

AstraZeneca and Amgen's Tezspire meets Phase 3 goals in eosinophilic esophagitis

Tezspire succeeded in a Phase 3 trial for eosinophilic esophagitis, potentially becoming the drug's third approved indication and positioning it to compete with Sanofi's Dupixent, currently the only approved biologic for the condition.

Aug 27, 2026·2 sources

00

Top claims

▪Tezspire is a monoclonal antibody designed to bind to and block thymic stromal lymphopoietin, a signaling protein implicated in epithelial-driven inflammatory conditions
▪Under their collaboration agreement, Amgen holds United States commercialization rights to Tezspire, while AstraZeneca records sales for the rest of the world
▪AstraZeneca and Amgen reported that the safety profile of Tezspire in the Phase 3 CROSSING trial was generally consistent with the drug's previously approved indications

Related timelines

AI Data Center Gold Rush

Crypto hacks

Iran War

Russia-Ukraine war

Trump administration